Abstract
Aim of the present Consensus Statement is to provide a comprehensive and up to-date document on the pathophysiology, atherogenicity and clinical significance of low density lipoproteins (LDL) subclasses. We sub-divided our Statement in 2 sections: section I discusses the pathophysiology, atherogenicity and measurement issues, while section II is focused on the effects of drugs and lifestlyle modifications. Suggestions for future research in the field are highlighted at the end of section II. Each section includes Conclusions.
Keywords: LDL, subclasses, atherosclerosis, cardiovascular risk, statement, hypertriglyceridaemia, coronary heart disease, cardiovascular disease, apolipoprotein, chylomicrons
Current Vascular Pharmacology
Title: “European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses
Volume: 9 Issue: 5
Author(s): Klaus G. Parhofer, Evangelos Liberopoulos, Matilda Florentin, Karl Winkler, Anthony S. Wierzbicki, Alexandros D. Tselepis, Gerald H. Tomkin, Giatgen A. Spinas, Giovam Battista Rini, Dimitri P. Mikhailidis, Winfried Marz, Jacqueline de Graaf, Vasilios Athyros, Alberto Zambon, Bruce Griffin, Kaspar Berneis, Manfredi Rizzo and Moses Elisaf
Affiliation:
Keywords: LDL, subclasses, atherosclerosis, cardiovascular risk, statement, hypertriglyceridaemia, coronary heart disease, cardiovascular disease, apolipoprotein, chylomicrons
Abstract: Aim of the present Consensus Statement is to provide a comprehensive and up to-date document on the pathophysiology, atherogenicity and clinical significance of low density lipoproteins (LDL) subclasses. We sub-divided our Statement in 2 sections: section I discusses the pathophysiology, atherogenicity and measurement issues, while section II is focused on the effects of drugs and lifestlyle modifications. Suggestions for future research in the field are highlighted at the end of section II. Each section includes Conclusions.
Export Options
About this article
Cite this article as:
G. Parhofer Klaus, Liberopoulos Evangelos, Florentin Matilda, Winkler Karl, S. Wierzbicki Anthony, D. Tselepis Alexandros, H. Tomkin Gerald, A. Spinas Giatgen, Battista Rini Giovam, P. Mikhailidis Dimitri, Marz Winfried, de Graaf Jacqueline, Athyros Vasilios, Zambon Alberto, Griffin Bruce, Berneis Kaspar, Rizzo Manfredi and Elisaf Moses, “European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses, Current Vascular Pharmacology 2011; 9 (5) . https://dx.doi.org/10.2174/157016111796642661
DOI https://dx.doi.org/10.2174/157016111796642661 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: (Persistent Elevation of Blood Pressure in Children and Adolescents is Associated with Arterial Hypertension and Premature Atherosclerosis in Adults. Is it Possible to Reverse this?)
Current Vascular Pharmacology The Role of Venous Abnormalities in Neurological Disease
Reviews on Recent Clinical Trials Haptoglobin Phenotype Correlates with the Extent of Cerebral Deep White Matter Lesions in Hypertensive Patients
Current Neurovascular Research Editorial [Hot Topic: Anti-Platelet Therapy (Guest Editor: Susan S. Smyth)]
Current Drug Targets Application of Mitochondria-Targeted Pharmaceuticals for the Treatment of Heart Disease
Current Pharmaceutical Design Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of Neuroendocrine Prostate Cancer
Current Pharmaceutical Design Personalized Medicine, Bioethics and Social Responsibilities: Re-thinking the Pharmaceutical Industry to Remedy Inequities in Patient Care and International Health
Current Pharmacogenomics and Personalized Medicine Synthesis, Single Crystal Study, in silico Analysis, in vitro Antiinflammatory and Anticancer Activities of 7-hydroxy-14H-naphtho[2,3- a]phenothiazine-8,13-dione
Drug Delivery Letters Berberine as a Potential Multi-Target Agent for Metabolic Diseases: A Review of Investigations for Berberine
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial [Hot Topic: The Medicinal Chemistry of Agents Targeting the Nuclear Hormone Receptor Guest Editor: John Regan ]
Current Topics in Medicinal Chemistry Use of Diuretics in Women for Management of Hypertension
Current Hypertension Reviews Endoplasmic Reticulum Stress and Atherosclerosis
Current Hypertension Reviews Algorithms and Criteria for Transcatheter Aortic Valve Replacement Patient Selection: Current Status and Future Trends
Current Pharmaceutical Design Role of miRNAs in Coronary Artery Disease
Current Signal Transduction Therapy Beta-Blockers for the Treatment of Essential Hypertension: What are the Arguments Against Their Use as First Line Therapy?
Current Hypertension Reviews Synthesis and Cytotoxic Activity of 4-Aryl-4H-chromeno[4,3-d] [1,2,3] selenadiazoles
Letters in Drug Design & Discovery Nutrition, Brain Aging, and Alzheimers Disease
Current Nutrition & Food Science Prevention of Bioprosthetic Heart Valve Calcification: Strategies and Outcomes
Current Medicinal Chemistry Cardiac Cell Therapy and Bypass Surgery
Current Pharmaceutical Design Lifelong Endocrine Fluctuations and Related Cognitive Disorders
Current Pharmaceutical Design